Navigation Links
Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
Date:9/19/2013

SAN DIEGO, Sept. 19, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the Company's participation at the BioCentury NewsMakers in the Biotech Industry conference at the Millennium Broadway Hotel in New York City on Friday, September 27, 2013.

Michael Martino, Ambit's CEO, will provide an overview of the Company and its lead drug candidate, quizartinib, at 8:30 a.m. EDT.  The presentation will be webcast live through the "Investors & Media" section of the Ambit website at www.ambitbio.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.Ambit Contacts:Marcy Graham

Ian Stone/
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
2. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
3. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
4. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
5. Ambit Biosciences to Present at Two Upcoming Investor Conferences
6. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
7. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
8. Natural Skin Care Solution, Probiotic Action Announces the Use of Their Probiotic Cleanser As a Anti-Acne Body Wash
9. Creabilis Announces Treatment of First Patients in its Phase 2b Trial of CT327 in Pruritus in Atopic Dermatitis Patients
10. Neogen announces 1st quarter results conference call
11. Global Industry Analysts, Inc. Announces the Launch of a Major Research Program Analysing the Global Market for Circulating Tumor Cells and Cancer Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... July 12 to take part in the first half of “Integrative Biotechnology,” an ... a partnership established in summer 2014, this course combines students from both universities ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... provide new insights on mechanics of fecal microbiota transplantation in C. difficile patients. ... the microbiome of patients undergoing fecal microbiota transplantation (FMT) as a treatment for ...
(Date:6/30/2015)... ... 30, 2015 , ... The maximum number of shares proposed to be purchased ... shares of unvested restricted stock). On June 29, 2015, the last trading day prior ... reported on the OTCBB was $2.29 per share. , The tender offer will expire ...
Breaking Biology Technology:Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3
... DIEGO, April 14 XIFIN Inc., the ... diagnostic laboratories, announced today that XIFIN,s CEO ... at the Executive War College Conference in ... attendance will be senior executives, laboratory administrators ...
... to begin after markets close at 2:00 p.m. PT (5:00 ... MASI ), the inventor of Pulse CO-Oximetry and Measure-Through ... first quarter 2009 financial results for the period ended April ... 2009.A conference call to review the results will begin at ...
... N.C., April 14 Pharmaceutical Institute (PI), the ... pharmaceutical and biotech industry, today announced the release ... Markets Excellence(TM) . The series was developed ... leaders from 17 large and midsize pharmaceutical and ...
Cached Biology Technology:XIFIN Inc. CEO to Speak at Executive War College Conference 2XIFIN Inc. CEO to Speak at Executive War College Conference 3Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 2Masimo to Report First Quarter 2009 Financial Results on May 5, 2009 3Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence 2Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence 3
(Date:6/16/2015)... NEW YORK , June 16, 2015  With ... the world, security remains a top concern. The recent ... confirms the need for strong authentication within government ... HYPR Token, a biometric one-time password (OTP) authenticator, has ... Processing Standards (FIPS) 140-2 Level 3 validation for tamper ...
(Date:6/15/2015)... , June 16, 2015 According ... Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, ... to 2020" published by MarketsandMarkets, The Natural Language Processing ... a CAGR of 18.4% for the forecast period 2015-2020. ...   46 F igures spread   through 155 ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... patent to electronically capture, analyze and identify participants ... recognition methods. This system can: ... an enrollment and subsequent sign-on process is actually ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... and other astute observers of nature have long known that ... the biochemical mechanisms that control this nightly stem elongation, common ... biologistsuntil now. In this week,s early online publication of ... California, San Diego report their discovery of a protein complex ...
... Tel Aviv Stem cells from early embryos can be ... revive and repair different areas of the body. Therapies based ... treatment of diabetes, but have been held back by medical ... are capitalizing on the "memories" of stem cells generated from ...
... Several types of cancer, including stomach, liver and colon, ... scientists have theorized that differences in lifestyle, such as diet ... suggests that the differences are rooted in basic biological differences ... new study from MIT shows that treating male mice with ...
Cached Biology News:Biologists discover an 'evening' protein complex that regulates plant growth 2Biologists discover an 'evening' protein complex that regulates plant growth 3Biologists discover an 'evening' protein complex that regulates plant growth 4Biologists discover an 'evening' protein complex that regulates plant growth 5Stem cell 'memory' can boost insulin levels 2Study explains why men are at higher risk for stomach cancer 2Study explains why men are at higher risk for stomach cancer 3
Biotin d anti-mouse Tim-1...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Anti-20S proteasome subunits alpha 1, 2, 3, 5, 6 & 7, clone MCP231 Immunogen: Dinitrophenylated proteasomes Molecular Weight: 29 and 32 kDa....
Anti-ADP-Ribosylation Factor 1, clone 3F1 Immunogen: Synthetic peptide corresponding to the C-terminal amino acid sequence of human ARF1. Available Date: 38495...
Biology Products: